Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease.

Sergeant N, Vingtdeux V, Eddarkaoui S, Gay M, Evrard C, Le Fur N, Laurent C, Caillierez R, Obriot H, Larchanché PE, Farce A, Coevoet M, Carato P, Kouach M, Descat A, Dallemagne P, Buée-Scherrer V, Blum D, Hamdane M, Buée L, Melnyk P.

Neurobiol Dis. 2019 Mar 27. pii: S0969-9961(18)30327-9. doi: 10.1016/j.nbd.2019.03.028. [Epub ahead of print]

PMID:
30928644
2.

Neuronal AMP-activated protein kinase hyper-activation induces synaptic loss by an autophagy-mediated process.

Domise M, Sauvé F, Didier S, Caillerez R, Bégard S, Carrier S, Colin M, Marinangeli C, Buée L, Vingtdeux V.

Cell Death Dis. 2019 Mar 4;10(3):221. doi: 10.1038/s41419-019-1464-x.

3.

Contribution of the Endosomal-Lysosomal and Proteasomal Systems in Amyloid-β Precursor Protein Derived Fragments Processing.

Evrard C, Kienlen-Campard P, Coevoet M, Opsomer R, Tasiaux B, Melnyk P, Octave JN, Buée L, Sergeant N, Vingtdeux V.

Front Cell Neurosci. 2018 Nov 22;12:435. doi: 10.3389/fncel.2018.00435. eCollection 2018.

4.

AMP-activated Protein Kinase Controls Immediate Early Genes Expression Following Synaptic Activation Through the PKA/CREB Pathway.

Didier S, Sauvé F, Domise M, Buée L, Marinangeli C, Vingtdeux V.

Int J Mol Sci. 2018 Nov 22;19(12). pii: E3716. doi: 10.3390/ijms19123716.

5.

AMP-Activated Protein Kinase Is Essential for the Maintenance of Energy Levels during Synaptic Activation.

Marinangeli C, Didier S, Ahmed T, Caillerez R, Domise M, Laloux C, Bégard S, Carrier S, Colin M, Marchetti P, Ghesquière B, Balschun D, Buée L, Kluza J, Vingtdeux V.

iScience. 2018 Nov 30;9:1-13. doi: 10.1016/j.isci.2018.10.006. Epub 2018 Oct 12.

6.

A phenotypic approach to the discovery of compounds that promote non-amyloidogenic processing of the amyloid precursor protein: Toward a new profile of indirect β-secretase inhibitors.

Gay M, Evrard C, Descamps F, Carato P, Renault N, Coevoet M, Eddarkaoui S, Baud C, Larchanché PE, Buée L, El Bakali J, Vingtdeux V, Sergeant N, Melnyk P.

Eur J Med Chem. 2018 Nov 5;159:104-125. doi: 10.1016/j.ejmech.2018.08.092. Epub 2018 Sep 22.

PMID:
30268822
7.

Study of AMPK-Regulated Metabolic Fluxes in Neurons Using the Seahorse XFe Analyzer.

Marinangeli C, Kluza J, Marchetti P, Buée L, Vingtdeux V.

Methods Mol Biol. 2018;1732:289-305. doi: 10.1007/978-1-4939-7598-3_19.

PMID:
29480483
8.

A modification-specific peptide-based immunization approach using CRM197 carrier protein: Development of a selective vaccine against pyroglutamate Aβ peptides.

Vingtdeux V, Zhao H, Chandakkar P, Acker CM, Davies P, Marambaud P.

Mol Med. 2017 Jan;22:841-849. doi: 10.2119/molmed.2016.00218. Epub 2016 Nov 28.

9.

AMPK in Neurodegenerative Diseases.

Domise M, Vingtdeux V.

Exp Suppl. 2016;107:153-177. Review.

PMID:
27812980
10.

AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo.

Domise M, Didier S, Marinangeli C, Zhao H, Chandakkar P, Buée L, Viollet B, Davies P, Marambaud P, Vingtdeux V.

Sci Rep. 2016 May 27;6:26758. doi: 10.1038/srep26758.

11.

CALHM1 deficiency impairs cerebral neuron activity and memory flexibility in mice.

Vingtdeux V, Chang EH, Frattini SA, Zhao H, Chandakkar P, Adrien L, Strohl JJ, Gibson EL, Ohmoto M, Matsumoto I, Huerta PT, Marambaud P.

Sci Rep. 2016 Apr 12;6:24250. doi: 10.1038/srep24250.

12.

Postnatal neurodevelopmental expression and glutamate-dependent regulation of the ZNF804A rodent homologue.

Chang EH, Kirtley A, Chandon TS, Borger P, Husain-Krautter S, Vingtdeux V, Malhotra AK.

Schizophr Res. 2015 Oct;168(1-2):402-410. doi: 10.1016/j.schres.2015.06.023. Epub 2015 Jul 8.

13.

AMPK in Neurodegenerative Diseases: Implications and Therapeutic Perspectives.

Marinangeli C, Didier S, Vingtdeux V.

Curr Drug Targets. 2016;17(8):890-907. Review.

PMID:
26073858
14.

CALHM1 ion channel elicits amyloid-β clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain.

Vingtdeux V, Chandakkar P, Zhao H, Blanc L, Ruiz S, Marambaud P.

J Cell Sci. 2015 Jul 1;128(13):2330-8. doi: 10.1242/jcs.167270. Epub 2015 May 21.

15.

Chloroquine and chloroquinoline derivatives as models for the design of modulators of amyloid Peptide precursor metabolism.

Melnyk P, Vingtdeux V, Burlet S, Eddarkaoui S, Grosjean ME, Larchanché PE, Hochart G, Sergheraert C, Estrella C, Barrier M, Poix V, Plancq P, Lannoo C, Hamdane M, Delacourte A, Verwaerde P, Buée L, Sergeant N.

ACS Chem Neurosci. 2015 Apr 15;6(4):559-69. doi: 10.1021/cn5003013. Epub 2015 Feb 6.

PMID:
25611616
16.

Effect of the CALHM1 G330D and R154H human variants on the control of cytosolic Ca2+ and Aβ levels.

Vingtdeux V, Tanis JE, Chandakkar P, Zhao H, Dreses-Werringloer U, Campagne F, Foskett JK, Marambaud P.

PLoS One. 2014 Nov 11;9(11):e112484. doi: 10.1371/journal.pone.0112484. eCollection 2014.

17.

Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β.

Ma T, Chen Y, Vingtdeux V, Zhao H, Viollet B, Marambaud P, Klann E.

J Neurosci. 2014 Sep 3;34(36):12230-8. doi: 10.1523/JNEUROSCI.1694-14.2014.

18.

Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke.

Gelé P, Vingtdeux V, Potey C, Drobecq H, Ghestem A, Melnyk P, Buée L, Sergeant N, Bordet R.

Proteome Sci. 2014 May 6;12:24. doi: 10.1186/1477-5956-12-24. eCollection 2014.

19.

CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease.

Koppel J, Vingtdeux V, Marambaud P, d'Abramo C, Jimenez H, Stauber M, Friedman R, Davies P.

Mol Med. 2014 Mar 14;20:29-36. doi: 10.2119/molmed.2013.00140.revised.

20.

CB₂ receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease.

Koppel J, Vingtdeux V, Marambaud P, d'Abramo C, Jimenez H, Stauber M, Friedman R, Davies P.

Mol Med. 2013 Nov 8;19:357-64. doi: 10.2119/molmed.2013.00140. Erratum in: Mol Med. 2014;20():37. Corrected and republished in: Mol Med. 2014;20:29-36.

Supplemental Content

Loading ...
Support Center